» Articles » PMID: 10395484

Effects of C-4 Stereochemistry and C-4' Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues

Overview
Journal J Med Chem
Specialty Chemistry
Date 1999 Jul 8
PMID 10395484
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Additional structure-activity studies of desferrithiocin analogues are carried out. The effects of stereochemistry at C-4 on the ligands' iron clearing efficiency are reviewed and assessed using the enantiomers 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(R)-carboxylic acid and 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid. The utility of 4'-hydroxylation as a method of reducing the toxicity of desazadesferrithiocin analogues is also examined further with the synthesis and in vivo comparison of 4, 5-dihydro-2-(2-hydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid, which is the natural product 4-methylaeruginoic acid, and 4, 5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid. The stereochemistry at C-4 is shown to have a substantial effect on the iron clearing efficiency of desferrithiocin analogues, as does C-4'-hydroxylation on the toxicity profile. All of the compounds are evaluated in a bile-duct-cannulated rodent model to determine iron clearance efficiency and are carried forward to the iron-overloaded primate for iron clearing measurements. On the basis of the results of the present work, although 4,5-dihydro-2-(2, 4-dihydroxyphenyl)thiazole-4(S)-carboxylic acid is still the most promising candidate for clinical evaluation, 4,5-dihydro-2-(2, 4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid (4'-hydroxydesazadesferrithiocin) also merits further preclinical assessment.

Citing Articles

Recent advances in the synthesis and utility of thiazoline and its derivatives.

Kumar S, Arora A, Sapra S, Kumar R, Singh B, Singh S RSC Adv. 2024; 14(2):902-953.

PMID: 38174252 PMC: 10759189. DOI: 10.1039/d3ra06444a.


Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor.

Chen Q, Chaturvedi P, Luesch H Org Process Res Dev. 2023; 22(2):190-199.

PMID: 37332527 PMC: 10275292. DOI: 10.1021/acs.oprd.7b00352.


Metabolically programmed iron chelators.

Bergeron R, Bharti N, McManis J, Wiegand J Bioorg Med Chem. 2015; 23(17):5954-71.

PMID: 26231739 PMC: 4608554. DOI: 10.1016/j.bmc.2015.06.059.


Desferrithiocin: a search for clinically effective iron chelators.

Bergeron R, Wiegand J, McManis J, Bharti N J Med Chem. 2014; 57(22):9259-91.

PMID: 25207964 PMC: 4255733. DOI: 10.1021/jm500828f.


Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Bergeron R, Wiegand J, Bharti N, McManis J J Med Chem. 2012; 55(16):7090-103.

PMID: 22889170 PMC: 3583384. DOI: 10.1021/jm300509y.